Justin Gainor
Harvard University
H-index: 80
North America-United States
Top articles of Justin Gainor
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor … | Journal of Clinical Oncology | Tony Mok Kazuhiko Nakagawa Keunchil Park Yuichiro Ohe Nicolas Girard | 2024/1/22 |
In silico clinical studies for optimal COVID-19 vaccination schedules in patients with cancer | Cell Reports Medicine | Chrysovalantis Voutouri C Corey Hardin Vivek Naranbhai Mohammad R Nikmaneshi Melin J Khandekar | 2024/3/19 |
Sarcopenia, adiposity and large discordance between cystatin C and creatinine‐based estimated glomerular filtration rate in patients with cancer | Journal of Cachexia, Sarcopenia and Muscle | Paul E Hanna Tianqi Ouyang Ismail Tahir Nurit Katz‐Agranov Qiyu Wang | 2024 |
Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy | Nature Immunology | Jonathan H Chen Linda T Nieman Maxwell Spurrell Vjola Jorgji Liad Elmelech | 2024/3/19 |
Three-year overall survival outcomes and correlative analyses in patients with non–small-cell lung cancer and high (50-89%) versus very high (≥ 90%) PD-L1 expression treated … | JTO Clinical and Research Reports | Biagio Ricciuti Arielle Elkrief Jessica Lin Jianjun Zhang Joao V Alessi | 2024/4/12 |
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study | Thyroid | Vivek Subbiah Mimi I Hu Aaron S Mansfield Matthew H Taylor Martin Schuler | 2024/1/1 |
Objective Analysis and Clinical Significance of the Spatial Tumor-Infiltrating Lymphocyte Patterns in Non-Small Cell Lung Cancer | Clinical Cancer Research | Miguel Lopez de Rodas Yvonne Wang Gang Peng Jianlei Gu Mari Mino-Kenudson | 2024/3/1 |
Abstract CT277: BGB-LC-201 (NCT05635708): A phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents+/-chemotherapy as … | Cancer Research | George Blumenschein Benjamin Besse Justin F Gainor DingZhi Huang Steven Kao | 2024/4/5 |
Current opportunities and challenges in ALK-positive lung cancer | Jessica J Lin Justin F Gainor | 2024/1/1 | |
Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib | JTO Clinical and Research Reports | Justin M Cheung Jiyoon Kang Beow Y Yeap Jennifer L Peterson Andrew Do | 2024/3/1 |
Abstract CT249: Results from KEYMAKER-U01 substudy 3: a phase 2 umbrella study of pembrolizumab plus investigational agents in patients with non-small-cell lung cancer (NSCLC … | Cancer Research | Charu Aggarwal James Stevenson Dariusz M Kowalski Tibor Csőszi Nir Peled | 2024/4/5 |
Osimertinib in Patients With Non–Small Cell Lung Cancer and Uncommon EGFR Mutations—Chasing Unicorns? | JAMA oncology | Victoria E Wang Justin F Gainor | 2024/1/1 |
Pralsetinib in patients with RET fusion–positive non-small-cell lung cancer: A plain language summary of the ARROW study | Frank Griesinger Giuseppe Curigliano Vivek Subbiah Christina S Baik Daniel SW Tan | 2024/2/1 | |
T-cell responses across heart, blood, and tumor in patients with immune checkpoint inhibitor-related myocarditis (irMyocarditis) | Cancer Research | Steven Blum Daniel A Zlotoff Neal P Smith Isabela J Kernin Swetha Ramesh | 2024/3/22 |
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors | Journal for immunotherapy of cancer | Jarushka Naidoo Catherine Murphy Michael B Atkins Julie R Brahmer Stephane Champiat | 2023 |
Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer | Nature communications | Lingzhi Hong Muhammad Aminu Shenduo Li Xuetao Lu Milena Petranovic | 2023/2/8 |
65O Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L) 1 inhibitor and … | Immuno-Oncology and Technology | N Leighl L Paz-Ares D Rodriguez Abreu R Hui S Baka | 2023/12/1 |
41P Efficacy of first-line (1L) nivolumab (N)+ ipilimumab (I) by tumor histologic subtype in patients (pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC) | Journal of Thoracic Oncology | H Borghaei D Balli L Paz-Ares M Reck SS Ramalingam | 2023/4/1 |
Brief report: declining rates of SARS-CoV-2 vaccine uptake among patients with thoracic malignancies | Clinical Lung Cancer | Catherine B Meador Vivek Naranbhai Grace Hambelton Julia Rivera Christopher S Nabel | 2023/6/1 |
Spatial analysis of human lung cancer reveals organized immune hubs enriched for stem-like CD8 T cells and associated with immunotherapy response | BioRxiv | Jonathan H Chen Linda T Nieman Maxwell Spurrell Vjola Jorgji Peter Richieri | 2023/4/6 |
Co-Authors
